SUPERNUS PHARMACEUTICALS, INC. Cash Provided by (Used in) Financing Activities, Discontinued Operations
SUPERNUS PHARMACEUTICALS, INC. (SUPN) reported Cash Provided by (Used in) Financing Activities, Discontinued Operations of -$1.97 million for the 12-month period ending 2011-12-31, per its 10-K filed 2014-03-21.
Discontinued › Cash Flow › Financing Activities
us-gaap:CashProvidedByUsedInFinancingActivitiesDiscontinuedOperations · last filed 2014-03-21
- SUPERNUS PHARMACEUTICALS, INC. cash provided by (used in) financing activities, discontinued operations for the quarter ending 2011-12-31 was $129.00K.
- SUPERNUS PHARMACEUTICALS, INC. cash provided by (used in) financing activities, discontinued operations for the quarter ending 2011-09-30 was -$1.28M.
- SUPERNUS PHARMACEUTICALS, INC. cash provided by (used in) financing activities, discontinued operations for the quarter ending 2011-06-30 was $925.00K.
- SUPERNUS PHARMACEUTICALS, INC. cash provided by (used in) financing activities, discontinued operations for the quarter ending 2011-03-31 was -$1.74M.
- SUPERNUS PHARMACEUTICALS, INC. cash provided by (used in) financing activities, discontinued operations for fiscal 2011 was -$1.97M, a 595.47% decline from fiscal 2010.
- SUPERNUS PHARMACEUTICALS, INC. cash provided by (used in) financing activities, discontinued operations for fiscal 2010 was $397.00K.
| Period end | Cash Provided by (Used in) Financing Activities, Discontinued Operations 3 month | Cash Provided by (Used in) Financing Activities, Discontinued Operations 6 month | Cash Provided by (Used in) Financing Activities, Discontinued Operations 9 month | Cash Provided by (Used in) Financing Activities, Discontinued Operations 12 month |
|---|---|---|---|---|
| 2011-12-31 | $129.00K derived: 10-K 12 month − 10-Q 9 month · filed 2014-03-21 | -$1.15M derived: sum of 2 quarters · filed 2014-03-21 | -$228.00K derived: sum of 3 quarters · filed 2014-03-21 | -$1.97M 10-K · filed 2014-03-21 |
| 2011-09-30 | -$1.28M derived: 10-Q 9 month − 10-Q 6 month · filed 2012-11-02 | -$357.00K derived: sum of 2 quarters · filed 2012-11-02 | -$2.10M 10-Q · filed 2012-11-02 | |
| 2011-06-30 | $925.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2012-08-13 | -$814.00K 10-Q · filed 2012-08-13 | ||
| 2011-03-31 | -$1.74M 10-Q · filed 2012-06-08 | |||
| 2010-12-31 | $397.00K 10-K · filed 2013-03-15 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Immunome Inc. (IMNM) | United States | $2.538B | -9.45 |
| Disc Medicine, Inc. (IRON) | United States | $2.553B | -11.40 |
| Nurix Therapeutics, Inc. (NRIX) | United States | $2.457B | -5.39 |
| SELLAS Life Sciences Group, Inc. (SLS) | United States | $2.420B | -91.87 |
| uniQure N.V. (QURE) | $2.416B | -4.93 | |
| Vera Therapeutics, Inc. (VERA) | United States | $2.402B | -7.67 |
| Harmony Biosciences Holdings, Inc. (HRMY) | United States | $2.399B | 11.67 |
| MBX Biosciences, Inc. (MBX) | United States | $2.664B | -25.36 |
| Mineralys Therapeutics, Inc. (MLYS) | United States | $2.353B | -6.82 |
| Viridian Therapeutics, Inc.\DE (VRDN) | United States | $2.342B | -5.38 |